REGENERON PHARMACEUTICALS (REGN) 693.58 +7.48 (+1.09%)
693.58 +7.48 (+1.09%)
US75886F1075 - Common Stock
| MRQ (2022-6-30) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 3.40B | 2.89B | 2.19B | 1.62B | 1.47B | |||
| Treasury Stock | -9.00B | -8.26B | -6.61B | -740.00M | -396.00M | |||
| Marketable Securities | 4.17B | 2.81B | 1.39B | 1.60B | 1.34B | |||
| Receivables | 5.16B | 6.04B | 4.12B | 2.67B | 2.24B | |||
| Inventories | 2.22B | 1.95B | 1.49B | 1.01B | 822.00M | |||
| Other Current Assets | 583.60M | 332.40M | 592.00M | 788.00M | 572.00M | |||
| Total Current Assets | 15.53B | 14.01B | 9.78B | 7.69B | 6.45B | |||
| Non-Current Assets | ||||||||
| PPE Net | 3.64B | 3.48B | 3.22B | 2.89B | 2.58B | |||
| Investments And Advances | 6.46B | 6.88B | 3.19B | 3.31B | 1.80B | |||
| Other Non-Current Assets | 1.57B | 1.06B | 968.00M | 913.00M | 911.00M | |||
| Total Non-Current Assets | 11.68B | 11.42B | 7.38B | 7.12B | 5.29B | |||
| TOTAL ASSETS | 27.21B | 25.43B | 17.16B | 14.80B | 11.73B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accounts Payable And Accrued Liabilities | 534.20M | 564.00M | 476.00M | 418.00M | 218.00M | |||
| Accrued Expenses | 1.93B | 1.88B | 1.50B | 1.04B | 751.00M | |||
| Other Current Liabilities | 566.30M | 768.30M | 720.00M | 641.00M | 473.00M | |||
| Total Current Liabilities | 3.03B | 3.93B | 2.70B | 2.10B | 1.44B | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 2.70B | 1.98B | 2.70B | 714.00M | 709.00M | |||
| Other Non-Current Liabilities | 783.40M | 753.50M | 745.00M | 905.00M | 826.00M | |||
| Total Non-Current Liabilities | 3.48B | 2.73B | 3.44B | 1.62B | 1.53B | |||
| TOTAL LIABILITIES | 6.52B | 6.67B | 6.14B | 3.72B | 2.98B | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Additional Paid In Capital | 9.12B | 8.09B | 6.72B | 4.43B | 3.91B | |||
| Shares Outstanding | 109.50M | 108.67M | 107.00M | 110.00M | 109.00M | |||
| Common Shares | 100.00K | 100.00K | 0.00 | 0.00 | 0.00 | |||
| Retained Earnings | 20.79B | 18.97B | 10.89B | 7.38B | 5.25B | |||
| Other Shareholders' Equity | -223.80M | -26.20M | 29.00M | 21.00M | -12.00M | |||
| Total Shareholders' Equity | 20.69B | 18.77B | 11.03B | 11.09B | 8.76B | |||
| TOTAL LIABILITIES AND EQUITY | 27.21B | 25.43B | 17.16B | 14.80B | 11.73B | |||
| Statistics | ||||||||
| Debt/Equity | 0.13 | 0.11 | 0.24 | 0.06 | 0.08 | |||
| Current Ratio | 5.12 | 3.56 | 3.63 | 3.67 | 4.47 | |||
| Return On Assets (ROA) | 20.90% | 31.75% | 20.47% | 14.29% | 20.83% | |||
| Return On Equity (ROE) | 27.49% | 43.03% | 31.87% | 19.08% | 27.91% | |||
All data in USD